With FDA clearance imminent, Petrovic says Insulet’s latest device offers real change in diabetes care.
Faced with either a bulky insulin pump or delivering multiple daily injections, Boston-based entrepreneur and venture capitalist John Brooks III sought an easier way to treat his young son’s newly diagnosed type 1 diabetes.
He assembled a team of engineers and they created Omnipod, Insulet’s (NSDQ:PODD) wearable, automated insulin delivery patch system.
“The company was founded in 2000 based on that innovation and ingenuity and that sort of spirit stays with the company,” CEO Shacey Petrovic said in an interview with Medical Design & Outsourcing. “We’re continuing to invest in innovation and look for a better way. The origin story was born of patient need and that is at the core of our mission.”